DCPH Deciphera Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DCPH

Price (delayed)

$14.62

Market cap

$1.18B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.29

Enterprise value

$1.12B

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase ...

Highlights
The gross profit is up by 27% year-on-year and by 9% since the previous quarter
Deciphera Pharmaceuticals's revenue has increased by 22% YoY and by 8% QoQ
Deciphera Pharmaceuticals's equity has decreased by 8% QoQ but it has increased by 2.7% YoY
Deciphera Pharmaceuticals's quick ratio has decreased by 16% YoY and by 15% from the previous quarter
The net income has contracted by 9% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.deciphera.com
Peers: OMER OMGA

Key stats

What are the main financial stats of DCPH
Market
Shares outstanding
80.8M
Market cap
$1.18B
Enterprise value
$1.12B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.34
Price to sales (P/S)
7.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.88
Earnings
Revenue
$163.36M
EBIT
-$194.51M
EBITDA
-$187.94M
Free cash flow
-$147.48M
Per share
EPS
-$2.29
Free cash flow per share
-$1.73
Book value per share
$4.38
Revenue per share
$1.92
TBVPS
$5.57
Balance sheet
Total assets
$473.57M
Total liabilities
$122.65M
Debt
$25.88M
Equity
$350.92M
Working capital
$280.82M
Liquidity
Debt to equity
0.07
Current ratio
3.8
Quick ratio
3.37
Net debt/EBITDA
0.31
Margins
EBITDA margin
-115%
Gross margin
97.7%
Net margin
-119.3%
Operating margin
-129.1%
Efficiency
Return on assets
-38.4%
Return on equity
-49.4%
Return on invested capital
-55.9%
Return on capital employed
-52.1%
Return on sales
-119.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DCPH stock price

How has the Deciphera Pharmaceuticals stock price performed over time
Intraday
-0.34%
1 week
-0.68%
1 month
-4.01%
1 year
2.09%
YTD
-9.36%
QTD
-7.06%

Financial performance

How have Deciphera Pharmaceuticals's revenue and profit performed over time
Revenue
$163.36M
Gross profit
$159.62M
Operating income
-$210.96M
Net income
-$194.94M
Gross margin
97.7%
Net margin
-119.3%
The gross profit is up by 27% year-on-year and by 9% since the previous quarter
Deciphera Pharmaceuticals's revenue has increased by 22% YoY and by 8% QoQ
The operating income has declined by 15% year-on-year
The net margin has increased by 11% year-on-year and by 7% since the previous quarter

Growth

What is Deciphera Pharmaceuticals's growth rate over time

Valuation

What is Deciphera Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.34
P/S
7.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.88
The company's EPS rose by 3.4% YoY
The P/B is 15% above the last 4 quarters average of 2.9 but 10% below the 5-year quarterly average of 3.7
Deciphera Pharmaceuticals's equity has decreased by 8% QoQ but it has increased by 2.7% YoY
DCPH's price to sales (P/S) is 87% less than its 5-year quarterly average of 58.9 and 8% less than its last 4 quarters average of 8.3
Deciphera Pharmaceuticals's revenue has increased by 22% YoY and by 8% QoQ

Efficiency

How efficient is Deciphera Pharmaceuticals business performance
The company's return on sales rose by 10% YoY and by 7% QoQ
The return on equity has grown by 3.9% year-on-year
Deciphera Pharmaceuticals's return on invested capital has decreased by 2% QoQ
The ROA has grown by 2.3% YoY

Dividends

What is DCPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DCPH.

Financial health

How did Deciphera Pharmaceuticals financials performed over time
Deciphera Pharmaceuticals's quick ratio has decreased by 16% YoY and by 15% from the previous quarter
Deciphera Pharmaceuticals's current ratio has decreased by 16% YoY and by 16% QoQ
The debt is 93% smaller than the equity
DCPH's debt to equity is down by 22% YoY
The debt has declined by 11% year-on-year and by 3.1% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.